CHMP recommends approval of Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone for the treatment of relapsed multiple myeloma

FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%

Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate

Sanofi to provide manufacturing support to Johnson & Johnson for their COVID-19 vaccine to help address global supply demands

Efanesoctocog alfa granted FDA Fast Track Designation for treatment of hemophilia A

The Lancet publishes Libtayo® (cemiplimab) data showing extended overall survival in patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%

Sanofi launches recommended cash offer for all shares in Kiadis

Offer Memorandum for All Outstanding Shares of Kiadis Pharma N.V.

FDA approves Libtayo® (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma

New indication for Plavix® (clopidogrel) now approved in the European Union